A 58-year-old man from rural Maharashtra presents with progressive fatigue and dyspnea on exertion for 6 months. He has a 12-year history of type 2 diabetes mellitus (HbA1c 9.2%) and hypertension (BP 158/94 mmHg on amlodipine 5 mg daily). Serum creatinine is 2.8 mg/dL (baseline 0.9 mg/dL 2 years ago), eGFR 22 mL/min/1.73m², urine protein-to-creatinine ratio 2.4 g/g, and hemoglobin 8.9 g/dL. Urinalysis shows 3+ proteinuria and no active sediment. What is the most appropriate next step in management to slow CKD progression?

Explanation

## Clinical Context This patient has CKD stage 3b–4 secondary to diabetic nephropathy with significant proteinuria (>2.5 g/day) and progressive renal function decline. Management must address both glycemic control and renal-protective strategies. ## Rationale for Correct Answer **Key Point:** SGLT2 inhibitors (empagliflozin, dapagliflozin) have proven cardiovascular and renal protection in both diabetic and non-diabetic CKD, independent of glucose lowering. They reduce proteinuria, slow eGFR decline, and lower mortality in CKD stages 2–4. **High-Yield:** The landmark EMPA-KIDNEY and DAPA-CKD trials demonstrated that SGLT2 inhibitors reduce the composite endpoint of CKD progression, cardiovascular death, and hospitalization by ~25–30% in CKD patients, making them first-line agents alongside ACE-I/ARB. **Clinical Pearl:** In diabetic CKD with proteinuria, the combination of: 1. ACE inhibitor or ARB (blocks efferent arteriolar vasoconstriction) 2. SGLT2 inhibitor (reduces glomerular hyperfiltration and tubular toxicity) 3. Optimized BP control (target <120 mmHg systolic in CKD) represents the evidence-based tripod for slowing progression. ## Why Anemia Management is Secondary Although hemoglobin is low (8.9 g/dL), ESA initiation is premature at eGFR 22. Current guidelines recommend: - First optimize iron stores and address reversible causes - Reserve ESA for symptomatic anemia or Hb <7 g/dL in CKD stage 4–5 - Prioritize renal-protective agents first [cite:Harrison 21e Ch 279]